Results 21 to 30 of about 2,215 (165)
Abstract INTRODUCTION We explored how people with dementia (PwD) and their carers navigate Peru's health system for diagnosis and treatment. METHODS We interviewed PwD (n = 4), carers (n = 18), and healthcare workers (n = 17) from four sites. We developed a patient journey map using thematic analysis and participant validation.
Daniela Rossini‐Vilchez +20 more
wiley +1 more source
Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy
Abstract INTRODUCTION A subset of Alzheimer's disease (AD) patients exhibits a procoagulant state that remains undiagnosed despite available treatments. We developed positron emission tomography (PET) strategies to in vivo detect cerebral microthrombi in TgCRND8 mice. METHODS PET was performed with a fibrin‐binding probe (FBP) in TgCRND8 and wild‐type
Carlos Ceron +22 more
wiley +1 more source
Prevalence of high‐risk plasma p‐tau217 levels and 5‐year transition of risk status in 70‐year‐olds
Abstract INTRODUCTION High‐risk plasma p‐tau217 levels predict amyloid‐β pathology in Alzheimer's disease, but little is known about the prevalence and temporal dynamics in the general population. METHODS Participants from the Gothenburg H70 Birth Cohort Study in Sweden were examined (n = 1157) and re‐examined after 5–7 years (n = 771).
Anna Dittrich +9 more
wiley +1 more source
Abstract INTRODUCTION Sleep and circadian rest–activity rhythm (RAR) disruption may bidirectionally relate to Alzheimer's disease (AD). Down syndrome (DS), the most common genetic cause of AD, presents sleep disorders, yet RAR patterns across the DS‐associated AD continuum remain uncharacterized. METHODS We analyzed 7‐day wrist actigraphy in 140 adults
Sandra Giménez +26 more
wiley +1 more source
Abstract INTRODUCTION This study investigates the evolution with disease progression and pathological correlates of peak width of skeletonized mean diffusivity (PSMD), a sensitive diffusion magnetic resonance imaging (MRI) marker of microvascular white matter (WM) injury, in sporadic Alzheimer's disease (sAD) and Down syndrome (DS)–associated AD (DSAD).
Alejandra O. Morcillo‐Nieto +27 more
wiley +1 more source
In vivo mapping of cortical amyloid beta‐myelin coupling in preclinical Alzheimer's disease
Abstract INTRODUCTION Accumulating evidence suggests that amyloid‐β (Aβ) preferentially deposits in poorly myelinated cortical regions and may interfere with remyelination. We hypothesized that this vulnerability would manifest as altered Aβ–myelin coupling in preclinical Alzheimer's disease (AD).
Mercedes Atienza, Jose L. Cantero
wiley +1 more source
Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants
Abstract INTRODUCTION The sortilin‐related receptor (SORL1) directs APP and Aβ trafficking within the retromer pathway. Cleavage at the cell surface releases soluble SORL1 (sSORL1) into cerebrospinal fluid (CSF). We examined whether CSF‐sSORL1 can serve as an in vivo marker of genetically impaired SORL1.
Matthijs W. J. de Waal +24 more
wiley +1 more source
Factors impacting survival in individuals with Down syndrome‐associated Alzheimer's disease
Abstract INTRODUCTION Adults with Down syndrome (DS) are at high risk for Alzheimer's disease (AD), the leading cause of death in this population. Survival in DS after AD diagnosis appears shorter than in sporadic AD; however, the factors influencing survival remain poorly understood.
Bessy Benejam +24 more
wiley +1 more source
Abstract INTRODUCTION White matter hyperintensities (WMH) are common in Down syndrome (DS), yet their longitudinal evolution and associations with Alzheimer's disease (AD) remain unclear. METHODS Longitudinal MRI study, including 80 DS adults and 53 euploid controls. WMH were segmented on serial FLAIR using a longitudinal pipeline.
Alejandra O. Morcillo‐Nieto +24 more
wiley +1 more source
Aim The aim is to assess the exposure to neuroendovascular intervention and perceptions among trainees in Latin America. Methods A descriptive and cross‐sectional study was conducted from October to December 2024 and was aimed at neurology residents and/or fellows in Latin American hospitals.
Miguel A. Vences +4 more
wiley +1 more source

